Autres langues Organon & Co.

Actions

OGN

US68622V1061

Marché Fermé - Nyse Autres places de cotation 22:00:02 18/04/2024			Varia. 5j.	Varia. 1 janv.
17,86 ^USD	-0,06 %		-2,30 %	+23,86 %

09/04	ORGANON & CO. : Morgan Stanley est neutre sur le titre	ZM
08/04	Le biosimilaire du dénosumab HLX14 de Shanghai Henlius Biotech atteint son point final	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	08/04
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	08/04
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	08/04
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	08/04
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	08/04
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray	20/03
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	08/03
Philips : une nouvelle directrice financière en octobre	28/02
New York attorney general urges stronger safety warning on asthma drug Singulair	23/02
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary	21/02
Organon's Hadlima Chosen by VA as Substitute for Humira	20/02
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary	20/02
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies	20/02
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	15/02
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued	15/02
Organon: Q4 Earnings Snapshot	15/02
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Organon & Co.

Actions

OGN

US68622V1061

Autres langues

Filtres